Additional Study Information: The purpose of this study is to test the safety of an investigational drug called ALN-BCAT, and find out what effects, if any, ALN-BCAT has on people with your type of liver cancer. The effects being studied include: the frequency and severity of side effects (to determine if the drug is safe); whether ALN-BCAT may make tumors smaller; how ALN-BCAT may affect the genes and proteins in your cancer cells; and how your body processes ALN-BCAT. ALN-BCAT is considered to be investigational, meaning it is not currently approved by the United States Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC). This is the first study in which ALN-BCAT will be given to people. High levels of a protein called Catenin beta-1(-catenin) have been seen in HCC cancer cells. ALN-BCAT is being studied to see if it will reduce the production of the -catenin protein in cancer cells that may lead to shrinking HCC tumors.